For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | 0 | 0 |
| Restructuring expenses | 0 | 0 | 0 | - |
| Research and development | 14,084,000 | 15,416,000 | 14,296,000 | 12,987,000 |
| General and administrative | 8,102,000 | 7,277,000 | 7,562,000 | 6,828,000 |
| Total operating expenses | 22,186,000 | 22,693,000 | 21,858,000 | 19,815,000 |
| Loss from operations | -22,186,000 | -22,693,000 | -21,858,000 | -19,815,000 |
| Other income, net | 3,295,000 | 2,359,000 | 2,263,000 | 2,519,000 |
| Net (loss) income | -18,891,000 | -20,334,000 | -19,595,000 | -17,296,000 |
| Unrealized loss on marketable securities | -687,000 | -115,000 | 159,000 | - |
| Total other comprehensive loss | -687,000 | -115,000 | 159,000 | - |
| Comprehensive (loss) income | -19,578,000 | -20,449,000 | -19,436,000 | - |
| Basic EPS | -0.25 | 0.109 | -0.31 | -0.28 |
| Diluted EPS | -0.25 | 0.109 | -0.31 | -0.28 |
| Basic Average Shares | 76,215,000 | -187,366,580 | 62,597,000 | 62,544,000 |
| Diluted Average Shares | 76,215,000 | -187,366,580 | 62,597,000 | 62,544,000 |
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)